Successful treatment with tenofovir in a child C cirrhotic patient with lamivudine‐resistant hepatitis B virus awaiting liver transplantation. Post‐transplant results

T. C. Taltavull,N. Chahri,B. Verdura,J. Gornals,Carmen López,A. Casanova,C. Cañas,J. Figueras,L. Casais
DOI: https://doi.org/10.1111/j.1432-2277.2005.00125.x
2005-07-01
Transplant International
Abstract:Antiviral treatment can be complex in decompensated hepatitis B virus (HBV) cirrhosis because of potential emergence of lamivudine‐resistant mutants and worsening liver function, and to multifactorial nephrotoxicity. Negative HBV‐DNA status by hybridization before liver transplantation is a favorable prognostic factor. We present the case of a 54‐year‐old HBV+ liver transplantation candidate who, after testing negative for HBV‐DNA, developed YMDD lamivudine‐resistant mutants resulting in a deteriorated clinical condition. After 8 months of adefovir plus lamivudine double therapy, only partial response was achieved. Tenofovir was added to this regimen, and an early decline of HBV‐DNA was seen at 4 weeks without adverse events. The patient underwent transplantation. At 21‐month postoperative follow‐up, the patient's outcome was excellent. Post‐transplantation HBV prophylaxis, taking into account the prior development of mutants, consists of hepatitis B immunoglobulin plus lamivudine and adefovir. Tenofovir was well tolerated and produced a fast antiviral response, suggesting its potential value in combined antiviral treatment for liver transplantation candidates.
What problem does this paper attempt to address?